Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Cervical Cancer Recurrent 1Breast Neoplasms 1

Interventions

Cystectomy 2toripalimab 1tislelizumab 1liposomal doxorubicin 1disitamab vedotin 1Surgical Procedures, Operative 1Rutin 1Radiation 1RC48 antibody 1Neoadjuvant Therapy 1Gemcitabine 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Muscle Invasive Bladder Cancer × RC48 antibody × Clear all
NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡